CD8A and lung cancer: Galectin-3 can promote macrophage differentiation to an M2-like phenotype and inhibit CD8+ T cell-mediated anti-tumor effects; therefore, galectin-3 deficiency or pharmacological blockade can significantly inhibit lung cancer progression [20].